| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 02/09/2006 | US20060029552 Carrier particles for use in dry powder inhalers |
| 02/08/2006 | EP1623714A2 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases |
| 02/08/2006 | EP1623221A2 Modulators of the p2y10 receptor useful in altering t lymphocyte function |
| 02/08/2006 | EP1623034A2 Mechanisms of myoblast transfer in treating heart failure |
| 02/08/2006 | EP1622914A2 New piperidinylamino-thieno 2,3-d pyrimidine compounds |
| 02/08/2006 | EP1622883A2 Compounds, compositions, and methods |
| 02/08/2006 | EP1622878A2 Compounds, compositions and methods |
| 02/08/2006 | EP1622685A1 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors |
| 02/08/2006 | EP1622639A2 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| 02/08/2006 | EP1622633A2 Treatment of t-cell mediated diseases |
| 02/08/2006 | EP1622632A2 Jucara and acai fruit-based dietary supplements |
| 02/08/2006 | EP1622628A2 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| 02/08/2006 | EP1622623A2 Methods of administering estrogens and progestins |
| 02/08/2006 | EP1622617A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 02/08/2006 | EP1622616A2 Inhibitors of akt activity |
| 02/08/2006 | EP1622613A2 Compounds, compositions and methods |
| 02/08/2006 | EP1622609A2 Methods for treating degenerative diseases/injuries |
| 02/08/2006 | EP1622608A2 Compositions and methods for treating cancer |
| 02/08/2006 | EP1622599A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/08/2006 | EP1622594A2 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 02/08/2006 | EP1622588A2 Delivery systems of homogeneous thermoreversible alginate films |
| 02/08/2006 | EP1622585A2 Lipid platinum complexes and methods of use thereof |
| 02/08/2006 | EP1622579A2 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
| 02/08/2006 | EP1622577A2 Prevention of deficits in neurogenesis with anti-inflammatory agents |
| 02/08/2006 | EP1622574A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 02/08/2006 | EP1622573A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/08/2006 | EP1622571A2 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
| 02/08/2006 | EP1622570A2 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| 02/08/2006 | EP1622569A2 Aza spiro alkane derivatives as inhibitors of metallproteases |
| 02/08/2006 | EP1622568A2 Interleukin-9 antagonist muteins and their pharmacological methods of use |
| 02/08/2006 | EP1622567A2 Androgen receptor modulators and methods of use thereof |
| 02/08/2006 | EP1622566A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| 02/08/2006 | EP1622564A2 Diazabicyclononene derivatives |
| 02/08/2006 | EP1622563A2 Improved heat shock protein-based vaccines and immunotherapies |
| 02/08/2006 | EP1622512A2 Systems and methods for respiratory event detection |
| 02/08/2006 | EP1622455A2 Gemini vitamin d3 compounds and methods of use thereof |
| 02/08/2006 | EP1622450A2 Method for promoting uninterrupted sleep by administration of trospium chloride |
| 02/08/2006 | EP1622448A2 Nasal administration of the lh-rh analog leuprolide |
| 02/08/2006 | CN1732165A 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| 02/08/2006 | CN1732146A Cycloalkyl inhibitors of potassium channel function |
| 02/08/2006 | CN1732015A Low dose methods for treating disorders in which TNF-alpha activity is detrimental |
| 02/08/2006 | CN1732006A 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as P2X7-inhibitors for the treatment of inflammatory diseases |
| 02/08/2006 | CN1731982A Method of treating insulin resistance, adult onset diabetes and metabolic syndrome X |
| 02/08/2006 | CN1731963A Stable topical drug delivery compositions |
| 02/08/2006 | CN1240718C Aggregates of human insulin derivatives |
| 02/07/2006 | US6996473 Method for screening and producing compound libraries |
| 02/07/2006 | US6995244 A mutant binding to prolactin receptor through site 1, does not bind through site 2 nor has diminished binding through site 2, and exhibits <1% of unmodified agonist activity; anticarcinogenic, -tumor and metastatis agents; breast/prostate cancer |
| 02/07/2006 | US6995180 for the treatment of diabetes, hyperglycemia, hypoglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, eating disorders, and nervous system disorders |
| 02/07/2006 | US6995167 Arylkylamine spirofuropyridines useful in therapy |
| 02/07/2006 | US6994863 Pharmaceutical and cosmetic carrier and composition for topical application |
| 02/07/2006 | US6994804 by using phosphite compounds containing the bis-cyclic structure of spiro phosphites, both rings being attached to the same tertiary carbon atom in the phosphite molecule; protect against discoloration for prolonged usage |
| 02/07/2006 | CA2340202C Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 02/02/2006 | WO2005056075A3 Transdermal system for sustained delivery of polypeptides |
| 02/02/2006 | WO2005048937A3 Package for pharmaceutical formulation |
| 02/02/2006 | WO2005046602A3 Vegf receptor antagonists |
| 02/02/2006 | WO2005041896A3 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| 02/02/2006 | WO2005032486A3 A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY |
| 02/02/2006 | WO2005007093A3 Uses of il-12 in hematopoiesis |
| 02/02/2006 | WO2005004809A3 Multivalent carriers of bi-specific antibodies |
| 02/02/2006 | WO2005002498A3 Methods of treating disorders caused by formation of transcripts carrying nonsense mutations |
| 02/02/2006 | WO2004110347A3 Compositions and methods for reducing scar tissue formation |
| 02/02/2006 | WO2004103286A3 Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent |
| 02/02/2006 | WO2004100877A3 Vaccine accelerator factor (vaf) for poultry |
| 02/02/2006 | WO2004098520A3 Compounds and compositions as protein kinase inhibitors |
| 02/02/2006 | WO2004093801A3 Pharmaceutical products |
| 02/02/2006 | WO2004087068A3 Cxcr4 antagonists and methods of their use |
| 02/02/2006 | WO2003096967A3 Dna vaccines encoding heat shock proteins |
| 02/02/2006 | US20060025590 Novel compounds |
| 02/02/2006 | US20060025452 Method of treating demyelinating diseases or conditions |
| 02/02/2006 | US20060025430 Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis |
| 02/02/2006 | US20060025394 Estradiol-related compounds and methods of use as anti-tumor agents |
| 02/02/2006 | US20060025385 L-DOPA amide derivatives and uses thereof |
| 02/02/2006 | US20060025372 Antisense modulation of PTP1B expression |
| 02/02/2006 | US20060024758 Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
| 02/02/2006 | US20060024682 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| 02/02/2006 | US20060024330 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 02/02/2006 | US20060024300 Immunoglobulin variants and uses thereof |
| 02/02/2006 | US20060024295 Method for treating lupus |
| 02/01/2006 | EP1620732A2 Claudins' underexpression as markers of tumor metastasis |
| 02/01/2006 | EP1620573A2 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| 02/01/2006 | EP1620555A2 Rhesus monkey bombesin receptor subtype-3 (brs-3), nucleotides encoding same, and uses thereof |
| 02/01/2006 | EP1620552A2 Use of glycodendrimer reagents for inhibiting adhesion by microorganisms |
| 02/01/2006 | EP1620550A2 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620459A2 An intracellular estradiol binding protein, a polynucleotide encoding the same and cell lines overexpressing the same |
| 02/01/2006 | EP1620451A2 Industrially scalable nucleoside synthesis |
| 02/01/2006 | EP1620429A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 02/01/2006 | EP1620413A2 Compounds, compositions, and methods |
| 02/01/2006 | EP1620411A2 Inhibitors of akt activity |
| 02/01/2006 | EP1620407A2 Oxo-pyrimidine compounds |
| 02/01/2006 | EP1620391A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 02/01/2006 | EP1620147A2 Apparatus and methods for repetitive microjet drug delivery |
| 02/01/2006 | EP1620127A2 Methods for treating taxol-induced gut disorder |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620118A2 Reversible pegylated drugs |
| 02/01/2006 | EP1620114A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films |
| 02/01/2006 | EP1620112A2 Desmoglein 4 is a novel gene involved in hair growth |
| 02/01/2006 | EP1620111A2 Controlled release formulation of erythromycin derivatives |
| 02/01/2006 | EP1620108A2 Pyrazole-amine compounds useful as kinase inhibitors |
| 02/01/2006 | EP1620102A2 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands |